Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Atyr Pharma Inc (NASDAQ: ATYR) was $1.0 for the day, down -1.96% from the previous closing price of $1.02. In other words, the price has decreased by -$1.96 from its previous closing price. On the day, 9.31 million shares were traded. ATYR stock price reached its highest trading level at $1.1 during the session, while it also had its lowest trading level at $1.0.
Ratios:
Our analysis of ATYR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.63 and its Current Ratio is at 5.63. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
On September 15, 2025, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $1.
Leerink Partners Downgraded its Outperform to Market Perform on September 15, 2025, while the target price for the stock was maintained at $1.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 08 ’25 when SCHIMMEL PAUL bought 682,001 shares for $0.90 per share. The transaction valued at 612,437 led to the insider holds 1,095,024 shares of the business.
SCHIMMEL PAUL bought 317,999 shares of ATYR for $299,364 on Oct 09 ’25. The Director now owns 1,413,023 shares after completing the transaction at $0.94 per share. On Mar 17 ’25, another insider, Gross Jane A, who serves as the Director of the company, bought 3,750 shares for $4.00 each. As a result, the insider paid 15,000 and bolstered with 9,750 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATYR now has a Market Capitalization of 97986632 and an Enterprise Value of 30129634.
Stock Price History:
The Beta on a monthly basis for ATYR is 0.74, which has changed by -0.66555184 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, ATYR has reached a high of $7.29, while it has fallen to a 52-week low of $0.68. The 50-Day Moving Average of the stock is -68.64%, while the 200-Day Moving Average is calculated to be -74.05%.
Shares Statistics:
ATYR traded an average of 11.29M shares per day over the past three months and 10356190 shares per day over the past ten days. A total of 97.99M shares are outstanding, with a floating share count of 94.81M. Insiders hold about 3.24% of the company’s shares, while institutions hold 63.58% stake in the company. Shares short for ATYR as of 1759190400 were 37932369 with a Short Ratio of 3.36, compared to 1756425600 on 29405110. Therefore, it implies a Short% of Shares Outstanding of 37932369 and a Short% of Float of 46.300000000000004.
Earnings Estimates
The stock of Atyr Pharma Inc (ATYR) is currently drawing attention from 11.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.06 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.59 and -$0.85 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.59, with 11.0 analysts recommending between -$0.22 and -$1.23.
